Physician profile
Terry J Lain
NPI 1295751006
$2,819.53
in general payments reported to CMS, 2019-2025
17 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Behavioral Neurology & Neuropsychiatry provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $208 · 2021: $732 · 2022: $588 · 2023: $320 · 2024: $435 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,108 · Education: $54.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.25 |
| Education | $54.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $419.78 | 2019-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $411.05 | 2021-2025 | |
| Indivior INC. | $367.39 | 2019-2025 | Sublocade, Perseris |
| Vanda Pharmaceuticals INC. | $305.84 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $251.71 | 2020-2022 | |
| Lundbeck LLC | $196.47 | 2020-2025 | Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $164.24 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $160.71 | 2020-2025 | Invega |
| Teva Pharmaceuticals USA, INC. | $155.79 | 2022-2024 | Austedo, Uzedy, Austedo Xr |
| Alkermes, INC. | $121.21 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $70.73 | 2024 | Cobenfy |
| Orexo US, INC. | $70.03 | 2021 | |
| Corium, LLC | $55.89 | 2022-2024 | Azstarys |
| Eisai INC. | $22.89 | 2021 | |
| Shire North American Group INC | $17.33 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $15.81 | 2019 | |
| Alfasigma USA, INC. | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Lain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.